WO2000015178A3 - Computer implemented pharmacokinetics method and program - Google Patents

Computer implemented pharmacokinetics method and program Download PDF

Info

Publication number
WO2000015178A3
WO2000015178A3 PCT/US1999/021001 US9921001W WO0015178A3 WO 2000015178 A3 WO2000015178 A3 WO 2000015178A3 US 9921001 W US9921001 W US 9921001W WO 0015178 A3 WO0015178 A3 WO 0015178A3
Authority
WO
WIPO (PCT)
Prior art keywords
tool
methods
computer
predicting
interest
Prior art date
Application number
PCT/US1999/021001
Other languages
French (fr)
Other versions
WO2000015178A2 (en
WO2000015178A9 (en
Inventor
George M Grass
Glen D Leesman
Daniel A Norris
Patrick J Sinko
John E Wehrli
Original Assignee
Navicyte Inc
George M Grass
Glen D Leesman
Daniel A Norris
Patrick J Sinko
John E Wehrli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navicyte Inc, George M Grass, Glen D Leesman, Daniel A Norris, Patrick J Sinko, John E Wehrli filed Critical Navicyte Inc
Priority to EP99949642A priority Critical patent/EP1144675A4/en
Priority to CA002344036A priority patent/CA2344036A1/en
Priority to JP2000569763A priority patent/JP2002524809A/en
Priority to AU62474/99A priority patent/AU768368B2/en
Publication of WO2000015178A2 publication Critical patent/WO2000015178A2/en
Publication of WO2000015178A3 publication Critical patent/WO2000015178A3/en
Publication of WO2000015178A9 publication Critical patent/WO2000015178A9/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/62—Design of libraries
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absoption of an administered compound of interest. The methods utilize the tools, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data. The PK tool of the invention may be provided as a computer system, as an article of manufacture in the form of a computer-readable medium, or a computer program product and the like. Subsystems and individual components of the PK tool also can be utilized and adapted in a variety of disparate applications for predicting the fate of an administered compound. The PK tool and methods of the invention can be used to screen and design compound libraries, select and design drugs, as well as predict drug efficacy in mammals from in vitro and/or in vivo data of one or more compounds of interest. The PK tool and methods of the invention also find use in selecting, designing, and preparing drug compounds, and multi-compound drugs and drug formulations (i.e., drug delivery system) for preparation of medicaments for use in treating mammalian disorders.
PCT/US1999/021001 1998-09-14 1999-09-14 Computer implemented pharmacokinetics method and program WO2000015178A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99949642A EP1144675A4 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method
CA002344036A CA2344036A1 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method
JP2000569763A JP2002524809A (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tools and methods
AU62474/99A AU768368B2 (en) 1998-09-14 1999-09-14 Pharmacokinetic-based drug design tool and method

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US10022498P 1998-09-14 1998-09-14
US10029098P 1998-09-14 1998-09-14
US60/100,290 1998-09-14
US60/100,224 1998-09-14
US10923298P 1998-11-18 1998-11-18
US10923498P 1998-11-18 1998-11-18
US60/109,232 1998-11-18
US60/109,234 1998-11-18
US32006999A 1999-05-26 1999-05-26
US09/320,270 1999-05-26
US09/320,545 1999-05-26
US09/320,371 US6647358B2 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,544 US20020010550A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,545 US6542858B1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,544 1999-05-26
US09/320,371 1999-05-26
US09/320,270 US20020035459A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,372 US20010041964A1 (en) 1998-09-14 1999-05-26 Pharmacokinetic-based drug design tool and method
US09/320,372 1999-05-26
US09/320,069 1999-05-26

Publications (3)

Publication Number Publication Date
WO2000015178A2 WO2000015178A2 (en) 2000-03-23
WO2000015178A3 true WO2000015178A3 (en) 2001-07-26
WO2000015178A9 WO2000015178A9 (en) 2001-10-04

Family

ID=27536966

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/021151 WO2000016231A1 (en) 1998-09-14 1999-09-14 Method for screening and producing compound libraries
PCT/US1999/021001 WO2000015178A2 (en) 1998-09-14 1999-09-14 Computer implemented pharmacokinetics method and program

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021151 WO2000016231A1 (en) 1998-09-14 1999-09-14 Method for screening and producing compound libraries

Country Status (8)

Country Link
US (6) US20010041964A1 (en)
EP (2) EP1185948B1 (en)
JP (2) JP2002524809A (en)
AT (1) ATE319136T1 (en)
AU (2) AU767944B2 (en)
CA (2) CA2343914A1 (en)
DE (1) DE69930137D1 (en)
WO (2) WO2000016231A1 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010487A6 (en) * 1996-06-11 1998-10-06 Unilin Beheer Bv FLOOR COATING CONSISTING OF HARD FLOOR PANELS AND METHOD FOR MANUFACTURING SUCH FLOOR PANELS.
US20040117125A1 (en) * 1999-04-26 2004-06-17 Hao Chen Drug discovery method and apparatus
US7759113B2 (en) 1999-04-30 2010-07-20 The General Hospital Corporation Fabrication of tissue lamina using microfabricated two-dimensional molds
US20070020662A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US20070021929A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
US20050089923A9 (en) * 2000-01-07 2005-04-28 Levinson Douglas A. Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US7216113B1 (en) * 2000-03-24 2007-05-08 Symyx Technologies, Inc. Remote Execution of Materials Library Designs
US7776021B2 (en) 2000-04-28 2010-08-17 The Charles Stark Draper Laboratory Micromachined bilayer unit for filtration of small molecules
US6549803B1 (en) * 2000-05-08 2003-04-15 Image-Guided Neurologics Inc. Method and apparatus for targeting material delivery to tissue
JP2004514879A (en) * 2000-07-28 2004-05-20 ライオン　バイオサイエンス　アクチェンゲゼルシャフト Pharmacokinetic tools and methods for predicting metabolism of compounds in mammals
US7319945B1 (en) * 2000-11-10 2008-01-15 California Institute Of Technology Automated methods for simulating a biological network
US6937257B1 (en) * 2001-01-31 2005-08-30 Pharsight Corporation Unit tracking and notification in a graphical drug model editor
US7043415B1 (en) * 2001-01-31 2006-05-09 Pharsight Corporation Interactive graphical environment for drug model generation
US20020111850A1 (en) * 2001-02-12 2002-08-15 Chevron Oronite Company Llc System and method for new product clearance and development
US6631291B2 (en) * 2001-05-18 2003-10-07 Instrumentarium Corp. Closed loop drug administration method and apparatus using EEG complexity for control purposes
US6957151B2 (en) * 2001-07-13 2005-10-18 Accelrys Software Inc. System and method for aqueous solubility prediction
DE10142019A1 (en) * 2001-08-28 2003-03-20 Philips Corp Intellectual Pty Circuit arrangement for demodulating signals
EP1487320A4 (en) * 2001-10-12 2010-12-01 Univ Utah Res Found Anesthesia drug monitor
US20030078760A1 (en) * 2001-10-19 2003-04-24 Globomax Holdings, Llc Population pharmacokinetic modeling and analysis (PDx-POP™)
US7027970B2 (en) * 2001-10-19 2006-04-11 Globomax Llc Tool for in vitro-in vivo correlation
US7415359B2 (en) * 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
US6799123B2 (en) * 2001-11-05 2004-09-28 Lyn Hughes Dissolution test equipment and method
DE10160270A1 (en) 2001-12-07 2003-06-26 Bayer Ag Computer system and method for calculating ADME properties
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
AU2003265228A1 (en) * 2002-03-12 2003-12-22 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
JP2005529158A (en) * 2002-05-28 2005-09-29 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Method, system and computer program product for computer analysis and design of amphiphilic polymers
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003269395A1 (en) * 2002-09-16 2004-04-30 Optimata, Ltd. An interactive technique for optimizing drug development from the pre-clinical phases through phase-iv
DE60318089T2 (en) * 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
DE10256315A1 (en) 2002-12-03 2004-06-17 Bayer Ag Computer system and method for calculating a pharmacokinetic behavior of a chemical substance in insects
DE602004022508D1 (en) * 2003-01-16 2009-09-24 Gen Hospital Corp USE OF THREE-DIMENSIONAL, MICRO-MANUFACTURED SYSTEMS FOR PHARMACOLOGICAL APPLICATIONS MANUFACTURED BY TISSUE TECHNOLOGY
US20040220785A1 (en) * 2003-01-21 2004-11-04 Van Osdol William W. Computational model for transdermal drug delivery
US7960166B2 (en) 2003-05-21 2011-06-14 The General Hospital Corporation Microfabricated compositions and processes for engineering tissues containing multiple cell types
US7853406B2 (en) * 2003-06-13 2010-12-14 Entelos, Inc. Predictive toxicology for biological systems
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
DE10345836A1 (en) * 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Method for simulating the interaction of chemical substances with living organisms
JP4247101B2 (en) * 2003-12-10 2009-04-02 株式会社東芝 Design support system
JP2005245667A (en) * 2004-03-03 2005-09-15 Koninkl Philips Electronics Nv Medicine administration design system
CN1969295B (en) * 2004-05-10 2011-06-08 皇家飞利浦电子股份有限公司 Data processing system and inspection device using the system
DE102004025534A1 (en) * 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Method for (two-stage) dose and dosage finding
WO2005116902A2 (en) * 2004-05-28 2005-12-08 Philips Intellectual Property & Standards Gmbh System for the noninvasive determination of tracer concentration in blood
US20070219729A1 (en) * 2004-05-28 2007-09-20 Koninklijke Philips Electronics, N.V. System for the Evaluation of Tracer Concentration in a Reference Tissue and a Target Region
US20050278124A1 (en) * 2004-06-14 2005-12-15 Duffy Nigel P Methods for molecular property modeling using virtual data
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
US8396670B2 (en) * 2004-08-16 2013-03-12 Venture Milling, Inc. Process, system and method for improving the determination of digestive effects upon an ingestable substance
WO2006060214A2 (en) * 2004-11-18 2006-06-08 The Regents Of The University Of California Apparatus and methods for manipulation and optimization of biological systems
EP2990073B1 (en) 2004-11-24 2018-05-02 Bayer Healthcare LLC Devices and systems for fluid delivery
WO2006066051A2 (en) * 2004-12-16 2006-06-22 Entelos, Inc. Methods and models for cholesterol metabolism
US20110046910A1 (en) * 2005-04-15 2011-02-24 Thermo Crs Ltd. Method and System for Sample Testing
US20070100558A1 (en) * 2005-05-02 2007-05-03 Walter Fontana Using biological models
US7331251B2 (en) * 2005-06-22 2008-02-19 Idaho State University Dissolution testing of solid dosage forms intended to be administered in the oral cavity
JP2009507228A (en) * 2005-08-31 2009-02-19 アフィーマックス・インコーポレイテッド Derivatization and low level detection of drugs in biological fluids and other solution matrices using proxy markers
WO2007094830A1 (en) * 2005-11-10 2007-08-23 In Silico Biosciences, Inc. Method and apparatus for computer modeling the human brain for predicting drug effects
DE102005061270A1 (en) * 2005-12-20 2007-06-28 Universität Hamburg Procedure for structure-based virtual screening of biologically active compounds, comprises categorizing and/or sorting the compounds in catalogue on the basis of their physicochemical and/or geometrical and/or structural characteristics
EP1884878A1 (en) * 2006-08-02 2008-02-06 Hitachi Ltd. Computer system for simulating a physical system
WO2008046045A1 (en) * 2006-10-12 2008-04-17 Cylene Pharmaceuticals, Inc. Drug biovailability screens
KR100856517B1 (en) 2007-01-03 2008-09-04 주식회사 인실리코텍 System, method and program for tissue target prediction of peptide sequence by mathematical model
EP3376504A1 (en) 2006-12-29 2018-09-19 Bayer Healthcare, LLC Patient-based parameter generation systems for medical injection procedures
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
BRPI0807737A2 (en) * 2007-03-30 2014-06-03 9898 Ltd PHARMACEUTICAL PLATFORM TECHNOLOGY FOR NATURAL PRODUCT DEVELOPMENT
US8718944B2 (en) * 2007-05-22 2014-05-06 Worcester Polytechnic Institute Patient-specific image-based computational modeling and techniques for human heart surgery optimization
US20090037539A1 (en) * 2007-08-02 2009-02-05 Telefonaktiebolaget Lm Ericsson (Publ) Methods and Systems for Message Interworking
EP2194874A4 (en) * 2007-09-21 2015-05-13 Nat Res Council Canada Method and apparatus for periodontal diagnosis
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
WO2009086550A1 (en) * 2008-01-03 2009-07-09 Abbott Laboratories Predicting long-term efficacy of a compound in the treatment of psoriasis
CN102065761B (en) * 2008-04-18 2014-09-03 生物氧动力有限公司 Imaging technique
US20100081861A1 (en) * 2008-04-24 2010-04-01 Searete Llc Computational System and Method for Memory Modification
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US8930208B2 (en) 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US8615407B2 (en) * 2008-04-24 2013-12-24 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US20090269329A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination Therapeutic products and systems
US8876688B2 (en) * 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100030089A1 (en) * 2008-04-24 2010-02-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100015583A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and method for memory modification
US20100125561A1 (en) * 2008-04-24 2010-05-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100041964A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20090271375A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment selection methods and systems
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20090270694A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20090312668A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US8606592B2 (en) 2008-04-24 2013-12-10 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20100022820A1 (en) * 2008-04-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US7974787B2 (en) 2008-04-24 2011-07-05 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
US8682687B2 (en) 2008-04-24 2014-03-25 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20090271009A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment modification methods and systems
US20100100036A1 (en) * 2008-04-24 2010-04-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US9649469B2 (en) * 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US9239906B2 (en) 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US20090270687A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for modifying bioactive agent use
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20100041958A1 (en) * 2008-04-24 2010-02-18 Searete Llc Computational system and method for memory modification
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20100063368A1 (en) * 2008-04-24 2010-03-11 Searete Llc, A Limited Liability Corporation Computational system and method for memory modification
US7801686B2 (en) * 2008-04-24 2010-09-21 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
KR100946145B1 (en) * 2008-05-13 2010-03-08 성균관대학교산학협력단 A Sequence Similarity Measuring Apparatus and Control Method thereof
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
WO2010048532A1 (en) * 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
US20100163034A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8694330B2 (en) * 2008-12-30 2014-04-08 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163025A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US8725529B2 (en) * 2008-12-30 2014-05-13 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163024A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Methods and systems for presenting an inhalation experience
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8712794B2 (en) * 2008-12-30 2014-04-29 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100166613A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8738395B2 (en) * 2008-12-30 2014-05-27 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100168525A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169260A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20100169259A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163027A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163036A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8706518B2 (en) * 2008-12-30 2014-04-22 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163038A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100168529A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100168602A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
EP2435831B1 (en) 2009-05-29 2014-11-26 Carl A. Wesolowski Method for evaluating renal function
CN105825049A (en) * 2009-10-19 2016-08-03 提拉诺斯公司 Integrated health data capture and analysis system
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
KR101298303B1 (en) * 2010-04-27 2013-08-20 울산대학교 산학협력단 COMBINATION ANALYSIS SYSTEM FOR Pharmacokinetic AND Pharmacodynamic MODELING OF DRUG
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2585116A4 (en) * 2010-06-24 2017-03-29 Bayer Healthcare LLC Modeling of pharmaceutical propagation and parameter generation for injection protocols
US9367812B2 (en) * 2010-08-25 2016-06-14 Optibrium Ltd. Compound selection in drug discovery
DE102010060311B3 (en) * 2010-11-02 2012-02-02 Freie Universität Berlin Method for supporting planning, implementation and analysis of clinical studies for e.g. pharmacological data of patient, involves computing value of measurable parameter based on variable that is characteristic for combined compartments
WO2012080949A1 (en) 2010-12-15 2012-06-21 Koninklijke Philips Electronics N.V. Contour guided deformable image registration
DE102011085180A1 (en) * 2011-10-25 2013-04-25 Piramal Imaging Sa Method for generating optimized tomography images
CN103077296B (en) * 2011-10-25 2015-11-18 复旦大学附属华山医院 Based on the in-vitro simulated method of the intravenous injection pharmacokinetic model of velocity of flow adjust
CN102682209B (en) * 2012-05-03 2014-11-05 桂林理工大学 Variable selection method for modeling organic pollutant quantitative structure and activity relationship
CA2873351C (en) 2012-05-14 2022-07-26 Bayer Medical Care Inc. Systems and methods for determination of pharmaceutical fluid injection protocols based on x-ray tube voltage
WO2014020428A2 (en) * 2012-08-02 2014-02-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method and computing system for modelling a primate brain
US20160335412A1 (en) * 2013-01-30 2016-11-17 Geoffrey Tucker Systems and methods for predicting and adjusting the dosage of medicines in individual patients
US20150147738A1 (en) * 2013-03-13 2015-05-28 Bowling Green State University Methods and systems for teaching biological pathways
WO2015017798A2 (en) 2013-08-02 2015-02-05 CRIXlabs, Inc. Method and system for predicting spatial and temporal distributions of therapeutic substance carriers
EP2911075A1 (en) * 2014-02-25 2015-08-26 LTS LOHMANN Therapie-Systeme AG System for determining a suitability of an agent for transdermal or transmucosal application and corresponding method
TW201618795A (en) 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
ES2891903T3 (en) 2015-02-17 2022-01-31 Cipherome Inc Method for selecting antineoplastic agent based on protein damage information of individuals to avoid antineoplastic agent side effects
GB2556787B (en) * 2015-07-29 2020-12-02 Synaptive Medical Barbados Inc Method, system and apparatus for adjusting image data to compensate for modality-induced distortion
EA201892347A1 (en) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед METHOD AND DEVICE FOR PROVIDING PHARMACOKINETIC SCHEME OF DOSING OF DRUGS
WO2017192997A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
JP7034102B2 (en) * 2016-06-30 2022-03-11 ギブン イメージング リミテッド Systems and methods for assessing and monitoring mucosal disease in the subject's gastrointestinal tract
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US10854326B2 (en) * 2017-11-21 2020-12-01 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
US11468973B2 (en) * 2018-02-02 2022-10-11 Richard Postrel Leveraging genomic, phenotypic and pharmacological data to cure disease
WO2020009916A1 (en) * 2018-07-03 2020-01-09 Yale University System and method for using microbiome to de-risk drug development
US11580275B1 (en) * 2018-12-18 2023-02-14 X Development Llc Experimental discovery processes
US20200234799A1 (en) * 2019-01-18 2020-07-23 Tata Consultancy Services Limited Method and system for insilico design and testing of formulations using physiochemical skin model
US20210050108A1 (en) * 2019-07-19 2021-02-18 Tata Consultancy Services Limited Systems and methods for generating optimized set of pharmacokinetic (pk) and pharmacodynamic (pd) parameters
CN110766084B (en) * 2019-10-28 2021-06-15 北京理工大学 Small sample SAR target identification method based on CAE and HL-CNN
JP7302621B2 (en) * 2021-04-02 2023-07-04 株式会社豊田中央研究所 Organic material transport property evaluation device and organic material transport property evaluation method
WO2022244022A1 (en) * 2021-05-21 2022-11-24 Aizen Algo Private Limited Method and system for prediction of time points in pharmacokinetic studies
WO2022248703A2 (en) 2021-05-27 2022-12-01 Cyprus University Of Technology Physiologically based toxicokinetic (pbtk) modeling for implant toxicology

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019359A1 (en) * 1994-01-12 1995-07-20 Massachusetts Institute Of Technology Process for making xanthene or cubane based compounds, and protease inhibitors
US5770384A (en) * 1994-12-22 1998-06-23 New England Medical Center Hospitals, Inc Method for determining compound interaction with E2 binding proteins
US5789160A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Parallel selex

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335438A (en) 1980-04-17 1982-06-15 Smolen Victor F Method and apparatus for automatic dissolution testing of products
US4411989A (en) 1981-08-13 1983-10-25 Midwest Research Institute Processes and devices for detection of substances such as enzyme inhibitors
GB2206429A (en) 1987-07-02 1989-01-05 Infrared Eng System determining properties or identity of a sample
US4775794A (en) 1987-11-02 1988-10-04 Zenon Environmental Inc. Process and apparatus for measurement of light-absorbable components dissolved in liquids
US4975581A (en) 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5680590A (en) 1990-09-21 1997-10-21 Parti; Michael Simulation system and method of using same
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
US5326778A (en) * 1992-03-03 1994-07-05 Research Corporation Technologies, Inc. Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
ATE234611T1 (en) 1993-04-20 2003-04-15 Tsrl Inc MULTI-STEP DRUG DELIVERY SYSTEM
US5703792A (en) 1993-05-21 1997-12-30 Arris Pharmaceutical Corporation Three dimensional measurement of molecular diversity
US5569452A (en) 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US5705335A (en) 1993-11-26 1998-01-06 Hendry; Lawrence B. Design of drugs involving receptor-ligand-DNA interactions
US5625579A (en) 1994-05-10 1997-04-29 International Business Machines Corporation Stochastic simulation method for processes containing equilibrium steps
ES2171542T3 (en) 1994-10-28 2002-09-16 Sophion Bioscience As PATCH-CLAMP DEVICE AND TECHNIQUE THAT HAVE HIGH PRODUCTION AND REQUIRE A SMALL VOLUME OF FLUID.
US5914891A (en) 1995-01-20 1999-06-22 Board Of Trustees, The Leland Stanford Junior University System and method for simulating operation of biochemical systems
US5699268A (en) 1995-03-24 1997-12-16 University Of Guelph Computational method for designing chemical structures having common functional characteristics
US5657255C1 (en) 1995-04-14 2002-06-11 Interleukin Genetics Inc Hierarchic biological modelling system and method
AU7525996A (en) 1995-11-03 1997-05-22 Eli Lilly And Company Automated permeability analysis system
WO1997020952A1 (en) 1995-12-07 1997-06-12 Scriptgen Pharmaceuticals, Inc. A fluorescence-based screening method for identifying ligands
US5783397A (en) 1995-12-11 1998-07-21 Northeastern University Screening natural samples for new therapeutic compounds using capillary electrophoresis
JP2000504672A (en) 1996-02-09 2000-04-18 フィテラ シンビオン エイピーエス Balanol analogues
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6235520B1 (en) 1996-06-27 2001-05-22 Cellstat Technologies, Inc. High-throughput screening method and apparatus
NZ333346A (en) 1996-06-28 2000-03-27 Caliper Techn Corp High-throughput screening assay systems in microscale fluidic devices
EP0818744A3 (en) 1996-07-08 1998-07-08 Proteus Molecular Design Limited Process for selecting candidate drug compounds
AU4330997A (en) 1996-08-29 1998-03-19 Chiron Corporation Method for analysing absorption, distribution, metabolism, excretion (ADME) an d pharmacokinetics properties of compound mixtures
US5854992A (en) 1996-09-26 1998-12-29 President And Fellows Of Harvard College System and method for structure-based drug design that includes accurate prediction of binding free energy
AU749281B2 (en) 1997-02-04 2002-06-20 Regents Of The University Of California, The Nanomolar, non-peptide inhibitors of cathepsin D
EP0918296A1 (en) 1997-11-04 1999-05-26 Cerep Method of virtual retrieval of analogs of lead compounds by constituting potential libraries

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789160A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Parallel selex
WO1995019359A1 (en) * 1994-01-12 1995-07-20 Massachusetts Institute Of Technology Process for making xanthene or cubane based compounds, and protease inhibitors
US5770384A (en) * 1994-12-22 1998-06-23 New England Medical Center Hospitals, Inc Method for determining compound interaction with E2 binding proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE DERWENT ON WEST CARELL ET AL.: "Biologically active molecule combinatorial library production - by reacting core molecule with tool molecules, especially for preparation of new xanthene derivative serine protease inhibitors", XP002932988 *
DATABASE DIALOG HOLFORD N.H.G.: "Drugmodel (pharmacokinetic modelling)" *
GEX-FABRY ET AL.: "pharmacokenetics of drugs", 1994, SPRINGER-VERLAG, BERLIN, XP002932986 *
HARVEY S.C.: "Remington's pharmaceutical sciences", 1990, MACK PUBLISHING CO., EASTON, PENNSYLVANIA, XP002932987 *
PROCEEDINGS OF THE FIFTH ANNUAL SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICINAL CARE, IEEE, 1981, NEW YORK, pages 603 - 606 *

Also Published As

Publication number Publication date
AU767944B2 (en) 2003-11-27
EP1185948B1 (en) 2006-03-01
AU6247499A (en) 2000-04-03
JP2002524809A (en) 2002-08-06
US6996473B2 (en) 2006-02-07
EP1185948A4 (en) 2002-06-26
US6647358B2 (en) 2003-11-11
EP1144675A2 (en) 2001-10-17
US20020013662A1 (en) 2002-01-31
WO2000015178A2 (en) 2000-03-23
JP2003521673A (en) 2003-07-15
DE69930137D1 (en) 2006-04-27
US20020010550A1 (en) 2002-01-24
EP1185948A1 (en) 2002-03-13
CA2344036A1 (en) 2000-03-23
AU6145199A (en) 2000-04-03
WO2000016231A1 (en) 2000-03-23
US20020061540A1 (en) 2002-05-23
US6542858B1 (en) 2003-04-01
WO2000015178A9 (en) 2001-10-04
CA2343914A1 (en) 2000-03-23
AU768368B2 (en) 2003-12-11
EP1144675A4 (en) 2007-05-02
US20010041964A1 (en) 2001-11-15
ATE319136T1 (en) 2006-03-15
US20020035459A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
WO2000015178A3 (en) Computer implemented pharmacokinetics method and program
NZ505914A (en) Three-dimensional structures and models of fc receptors and uses thereof
DE69518334T2 (en) PHARMACEUTICAL AEROSOL WHICH CONTAINS AT LEAST ONE SUGAR
AR023939A1 (en) COMPUTERS DERIVED FROM PIPERIDINE USEFUL AS AN ANTHOGONIST OF CCR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THE USE OF THE SAME ONLY OR IN COMBINATION WITH ANOTHER ANTIVIRAL AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND A KIT
BR9915095A (en) Pharmaceutical composition administered in aerosol
GEP20022839B (en) 2-(Purin-9-Yl)-Tetrahydrofuran-3,4-Diol Derivatives
GEP20063985B (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
PL336885A1 (en) Therapeutic products in the aerosol form
EP1908463A3 (en) Methods of inducing ovulation using a non-polypeptide camp level modulator
WO2002087567A3 (en) Polymethoxylated flavones for treating insulin resistance
WO2002085296A3 (en) Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
BR0110837A (en) Combination Chemotherapy
BR0212857A (en) Formulations and use of these
BR0008713A (en) Processes for preparing oral pharmaceutical formulations and compositions with ecb
WO2004028476A3 (en) Artemisinin-derived trioxane dimers
Rao et al. Deuterated Drugs
Murry et al. Influence of phenytoin on the disposition of irinotecan: a case report
DE69812086D1 (en) GLYCOSYLATED-GINKGOLID DERIVATIVES, THEIR USE AS MEDICINAL PRODUCTS AND THE PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEY
BRPI0515891A (en) method for producing a medical aerosol product and a medical aerosol product
Karl et al. Pharmacokinetics of oral triazolam in children
MY135460A (en) Method of stimulating hair growth using benzopyrans
Farber et al. Clinical studies of actinomycin D with special reference to Wilms’ tumor in children
Spector Effect of beta-adrenergic agents on skin test responses and bronchial challenge responses
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists
IT1237509B (en) COMPLEXES WITH THE CYCLODESTRINE INDICATED FOR THE TREATMENT OF ALL ANEMIC FORMULATIONS FROM LACK OF FOLATES, THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2344036

Country of ref document: CA

Ref country code: CA

Ref document number: 2344036

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 569763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 62474/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999949642

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09786361

Country of ref document: US

AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 114-126, DESCRIPTION, REPLACED BY NEW PAGES 114-129; PAGES 127-170, CLAIMS, REPLACED BY NEW PAGES 130-173; PAGES 1/35-35/35, DRAWINGS, REPLACED BY NEW PAGES 1/38-38/38; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999949642

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 62474/99

Country of ref document: AU